|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM245989749 |
| 003 |
DE-627 |
| 005 |
20231224142108.0 |
| 007 |
tu |
| 008 |
231224s2015 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0820.xml
|
| 035 |
|
|
|a (DE-627)NLM245989749
|
| 035 |
|
|
|a (NLM)25656013
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Wada, Naoki
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder
|b videourodynamic evaluation
|
| 264 |
|
1 |
|c 2015
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.04.2015
|
| 500 |
|
|
|a Date Revised 25.11.2016
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Using a videourodynamic study, we examined the efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder. We retrospectively studied 7 patients with neurogenic bladder (5 males and 2 females) who had detrusor overactivity (DO) or low compliance bladder (＜10 ml/cmH2O) despite taking anticholinergic medication. Bladder deformity was categorized from G0 to G3 by Ogawa's classification. Mean age of study patients was 51 years (25-76). Underlying diseases were spinal cord injury in 3 patients, spina bifida in 2, spinal cord infarction in 1, and post-radical hysterectomy in 1. Preceding anticholinergic medication was solifenacin 5 mg in 1 patient, solifenacin 10 mg in 5, and tolterodine 4 mg in 1. Before mirabegron, bladder deformity was G1 in 4 patients, G2 in 1 and G3 in 2, and vesicoureteral reflux (VUR) was detected in 3 patients. Five and 4 patients had detrusor overactivity and low compliance bladder, respectively. Videourodynamic study was reevaluated at a mean of 7 months (2- 12 months) after mirabegron. After mirabegron, urinary incontinence was improved in all patients. G3 bladder deformity was improved to G2 and G1 in one patient each, and VUR disappeared in all 3 patients. DO disappeared in 2 of the 5 patients, and bladder compliance was improved in all 4 patients with low compliance bladder. In conclusion, combination therapy of mirabegron is effective and beneficial for anticholinergic-resistant neurogenic bladder
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Acetanilides
|2 NLM
|
| 650 |
|
7 |
|a Cholinergic Antagonists
|2 NLM
|
| 650 |
|
7 |
|a Thiazoles
|2 NLM
|
| 650 |
|
7 |
|a mirabegron
|2 NLM
|
| 650 |
|
7 |
|a MVR3JL3B2V
|2 NLM
|
| 700 |
1 |
|
|a Okazaki, Satoshi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kobayashi, Shin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hashizume, Kazumi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kita, Masafumi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Matsumoto, Seiji
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kakizaki, Hidehiro
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 61(2015), 1 vom: 07. Jan., Seite 7-11
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:61
|g year:2015
|g number:1
|g day:07
|g month:01
|g pages:7-11
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 61
|j 2015
|e 1
|b 07
|c 01
|h 7-11
|